Abstract
The impact of pharmacy mediated conversion from intravenous to oral corticosteroids in patients with an exacerbation of chronic obstructive pulmonary disease
Highlights
Chronic obstructive pulmonary disease (COPD) is a common respiratory condition involving the airways characterized by airflow limitation [1,2]
A pharmacist investigator used a computerized medical record system to identify patients discharged with an International Classification of Disease, Ninth Revision (ICD-9) code of 491, 492, or 496 indicating a diagnosis of chronic obstructive pulmonary disease (COPD) exacerbation
The mean duration of IV corticosteroid use did not differ between the control and post intervention groups (2.9 ± 1.7 days vs 2.8 ± 1.9 days; P = 0.62)
Summary
Chronic obstructive pulmonary disease (COPD) is a common respiratory condition involving the airways characterized by airflow limitation [1,2]. It affects almost 15.7 million American (6.4%) and is associated with high morbidity and mortality [3]. There are numerous published reports demonstrating the benefit of conversion from intravenous (IV) to oral therapy including antimicrobials, acid suppressants, and antihypertensives [5,6,7]. This creates a mutually beneficial relationship for the hospital and patient by decreasing drug costs, reducing the risks of adverse drug reactions related to IV access, and potentially shortening hospital length of stay [5,6,7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
